Gossamer Bio Capital Expenditures (CapEx) Growth & History (GOSS)
Gossamer Bio's capital expenditures (capex) was $79,000 for fiscal 2025.
View full Gossamer Bio company overviewGossamer Bio annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $79,000 | $79,000 | — |
| 2024 | 2024-12-31 | $0 | $0 | — |
| 2023 | 2023-12-31 | $0 | −$410,000 | — |
| 2022 | 2022-12-31 | $410,000 | −$1.1M | −73.48% |
| 2021 | 2021-12-31 | $1.5M | $43,000 | +2.86% |
| 2020 | 2020-12-31 | $1.5M | −$1.5M | −49.33% |
| 2019 | 2019-12-31 | $3.0M | −$524,000 | −15.01% |
| 2018 | 2018-12-31 | $3.5M | — | — |
Gossamer Bio quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$53,000 | — |
| Q1 2026 | 2026-03-31 | $0 | −$26,000 | — |
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $53,000 | $53,000 | — |
| Q1 2025 | 2025-03-31 | $26,000 | $26,000 | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $0 | $0 | — |
| Q1 2024 | 2024-03-31 | $0 | $0 | — |
| Q3 2023 | 2023-09-30 | $0 | −$31,000 | — |
| Q2 2023 | 2023-06-30 | $0 | −$120,000 | — |
| Q1 2023 · Mar 31 | 2023-03-31 | $0 | −$157,000 | — |
| Q4 2022 | 2022-12-31 | $102,000 | $19,000 | +22.89% |
| Q3 2022 | 2022-09-30 | $31,000 | −$492,000 | −94.07% |
| Q2 2022 | 2022-06-30 | $120,000 | −$18,000 | −13.04% |
| Q1 2022 | 2022-03-31 | $157,000 | −$645,000 | −80.42% |
| Q4 2021 | 2021-12-31 | $83,000 | −$167,000 | −66.80% |
| Q3 2021 | 2021-09-30 | $523,000 | $224,000 | +74.92% |
| Q2 2021 | 2021-06-30 | $138,000 | −$303,000 | −68.71% |
| Q1 2021 | 2021-03-31 | $802,000 | $289,000 | +56.34% |
| Q4 2020 | 2020-12-31 | $250,000 | −$278,000 | −52.65% |
| Q3 2020 | 2020-09-30 | $299,000 | −$412,000 | −57.95% |
| Q2 2020 | 2020-06-30 | $441,000 | −$939,000 | −68.04% |
| Q1 2020 | 2020-03-31 | $513,000 | $166,000 | +47.84% |
| Q4 2019 | 2019-12-31 | $528,000 | $206,000 | +63.98% |
| Q3 2019 | 2019-09-30 | $711,000 | −$1.0M | −58.57% |
| Q2 2019 | 2019-06-30 | $1.4M | $439,000 | +46.65% |
| Q1 2019 | 2019-03-31 | $347,000 | −$164,000 | −32.09% |
| Q4 2018 | 2018-12-31 | $322,000 | — | — |
| Q3 2018 | 2018-09-30 | $1.7M | — | — |
| Q2 2018 | 2018-06-30 | $941,000 | — | — |
| Q1 2018 | 2018-03-31 | $511,000 | — | — |
Gossamer Bio capital expenditures (capex) trends
Over the last five fiscal years, Gossamer Bio's capital expenditures (capex) decreased from $1.5M to $79,000, a change of −$1.4M. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gossamer Bio source filings ↗